Plant Molecular Farming Unit, Division of Biotechnology, Institute of Agrobiological Sciences, National Agriculture and Food Research Organization, Kannondai 2-1-2, Tsukuba, Ibaraki, 305-8602, Japan.
Plant Cell Rep. 2018 Feb;37(2):209-223. doi: 10.1007/s00299-017-2220-2. Epub 2017 Oct 26.
Bioactive peptide was produced by fusion to rice prolamins in transgenic rice seeds. Their accumulation levels were affected by their deposition sites and by compensatory rebalancing between prolamins within PB-Is. Peptide immunotherapy using analogue peptide ligands (APLs) is one of promising treatments against autoimmune diseases. Use of seed storage protein as a fusion carrier is reasonable strategy for production of such small size bioactive peptides. In this study, to examine the efficacy of various rice prolamins deposited in ER-derived protein bodies (PB-Is), the APL12 from the Glucose-6-phosphate isomerase (GPI325-339) was expressed by fusion to four types of representative prolamins under the control of the individual native promoters. When the 14 and 16 kDa Cys-rich prolamins, which were localized in middle layer of PB-Is, were used for production of the APL12, they highly accumulated in transgenic rice seeds (~ 200 µg/grain). By contrast, fusion to the 10 and 13 kDa prolamins, which were localized in the core and outermost layer of PB-Is, resulted in lower levels of accumulation (~ 40 µg/grain). These results suggest that accumulation levels were highly affected by their deposition sites. Next, when different prolamin/APL12 fusion proteins were co-expressed to increase accumulation levels, they could not be increased so much as their expected additive levels. High accumulation of one type prolamin/APL12 led to reduction of other type(s) prolamin/APL12 to maintain the limited amounts of prolamins that can be deposited in PB-Is. Moreover, suppression of endogenous seed proteins by RNA interference also did not significantly enhance the accumulation levels of prolamin/APL12. These findings suggest that there may be compensatory rebalancing mechanism that controls the accumulation levels of prolamins deposited within PB-Is.
生物活性肽通过与转基因水稻种子中的水稻醇溶蛋白融合而产生。它们的积累水平受其沉积部位和 PB-I 内醇溶蛋白之间的补偿性再平衡的影响。使用类似肽配体 (APL) 的肽免疫疗法是治疗自身免疫性疾病的一种很有前途的方法。将种子贮藏蛋白用作融合载体是生产这种小尺寸生物活性肽的合理策略。在这项研究中,为了研究沉积在 ER 衍生的蛋白体 (PB-I) 中的各种水稻醇溶蛋白的功效,将来自葡萄糖-6-磷酸异构酶 (GPI325-339) 的 APL12 通过融合到四种类型的代表醇溶蛋白下来表达,这些醇溶蛋白受各自天然启动子的控制。当将定位于 PB-I 中层的 14 和 16 kDa 富含半胱氨酸的醇溶蛋白用于生产 APL12 时,它们在转基因水稻种子中高度积累(200μg/grain)。相比之下,与定位于 PB-I 核心和最外层的 10 和 13 kDa 醇溶蛋白融合导致积累水平较低(40μg/grain)。这些结果表明,积累水平受其沉积部位的高度影响。接下来,当不同的醇溶蛋白/APL12 融合蛋白被共表达以增加积累水平时,它们不能像预期的加性水平那样增加。一种类型的醇溶蛋白/APL12 的高积累导致其他类型的醇溶蛋白/APL12 的减少,以维持可以沉积在 PB-I 中的有限数量的醇溶蛋白。此外,通过 RNA 干扰抑制内源性种子蛋白也没有显著提高醇溶蛋白/APL12 的积累水平。这些发现表明,可能存在一种补偿性再平衡机制,控制沉积在 PB-I 内的醇溶蛋白的积累水平。